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Abstract
The DNA base excision-repair pathway is responsible for the repair of DNA damage caused by oxidation/alky-
lation and protects cells against the effects of endogenous and exogenous agents. Removal of the damaged base
creates a baseless (AP) site. AP endonuclease1 (Ape1) acts on this site to continue the BER-pathway repair. Fail-
ure to repair baseless sites leads to DNA strand breaks and cytotoxicity. In addition to the repair role of Ape1,
it also functions as a major redox-signaling factor to reduce and activate transcription factors such as AP1, p53,
HIF-1, and others that control the expression of genes important for cell survival and cancer promotion and
progression. Thus, the Ape1 protein interacts with proteins involved in DNA repair, growth-signaling path-
ways, and pathways involved in tumor promotion and progression. Although knockdown studies with siRNA
have been informative in studying the role of Ape1 in both normal and cancer cells, knocking down Ape1 does
not reveal the individual role of the redox or repair functions of Ape1. The identification of small-molecule in-
hibitors of specific Ape1 functions is critical for mechanistic studies and translational applications. Here we dis-
cuss small-molecule inhibition of Ape1 redox and its effect on both cancer and endothelial cells. Antioxid. Re-
dox Signal. 10, 1853–1867.
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Introduction
THE DNA BASE EXCISION-REPAIR (BER) pathway is respon-sible for the repair of DNA caused by oxidative, alkyla-
tion, and ionizing radiation and thus protects cells against
the toxic effects of endogenous and exogenous agents. Re-
moval of the incorrect or damaged base by a DNA glycosy-
lase, either a simple glycosylase such as the methylpurine
DNA glycosylase (MPG or AAG) or a complex glycosylase
(Ogg1, Nth1, NEIL1, etc.) composes the first step of the BER
pathway (Fig. 1). MPG repairs the alkylated DNA major cy-
totoxic lesion, 3-methyladenine (3-me A) and also functions
to cleave a major product of lipid oxidation; 1,N(6)-ethenoad-
enine. Ogg1, Nth1, NEIL1, and NEIL2 recognize and remove
both purine and pyrimidine oxidative DNA-damaged
adducts. All of these glycosylases require the further pro-
cessing of the initiating step in the BER pathway by Ape1
(Fig. 1). Ape1 (apurinic/apyrimidinic endonuclease 1) is the
major repair protein for abasic sites, accounting for 95% of
all AP endonuclease activity (77). It cleaves 5 of the abasic
site generating a normal 3-hydroxyl group and an abasic
deoxyribose-5-phosphate, which is processed by subsequent
enzymes of the BER pathway. The removal of a damaged
base results in an AP site that, if not repaired, may result in
a block to DNA replication and genetic instability (77). DNA
polymerase  is recruited to the abasic site by Ape1 and can
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use the 3OH as a substrate once it has removed the 5 de-
oxyribose phosphate terminus. DNA ligase I then ligates the
remaining break in the phosphodiester backbone, complet-
ing the repair. Other enzymatic repair activities associated
with Ape1 include 3-repair diesterase or phosphatase ac-
tivity (62), which is important for repair of DNA damaged
by IR, and a 3-5 exonuclease activity, reported to play a
role in the excision of deoxyribonucleoside analogues (7–10).
However, Ape1 also has another major cellular function:
Ape1 functions as a reduction–oxidation (redox) factor and
stimulates the DNA-binding activity of numerous transcrip-
tion factors that are involved in cancer promotion and pro-
gression, such as AP-1 (Fos/Jun), NF-B, PAX, HIF-1, HLF,
p53, and others (Fig. 1) (16, 21, 71). The redox function of
Ape1 is only found in mammals and not in other vertebrates,
as demonstrated by the lack of redox function of the ze-
brafish Ape1 (zApe1) (Fig. 2). The acquisition of the redox
function in Ape1 proteins is discussed in a recent publica-
tion (25). Each of the molecularly distinct functional domains
of Ape1, redox and repair, are completely independent in
their function [i.e., mutations of the cysteine at position 65
Cys65 (C65) removes the redox function but does not affect
LUO ET AL.1854
FIG. 1. Oxidative and alkylation DNA damage is effectively repaired by the DNA BER pathway. This is a very sim-
plified drawing of the DNA BER pathway. For a more detailed discussion, see Fishel et al. (21). (A) Damaged bases (in this
case an N3-adenine) are removed by glycosylases that result in baseless or apurinic (AP) sites. Ape1 acts on AP sites, pro-
duces a nick that allows É-polymerase to insert the correct base and DNA ligase to connect the DNA backbone. (B) In ad-
dition to its repair function, Ape1 also serves as a redox factor maintaining transcription factors in an active reduced state.
Some example targets are shown. Therefore, the protection of Ape1 from DNA damage may be twofold: directly through
its DNA-repair function and indirectly through its redox activity by enabling transcription factors to bind to DNA and re-
spond to the DNA damage. Lack of Ape1 activity may lead to cell death.
FIG. 2. Comparison of selected Ape1 family members
from bacteria to mammals. The percentage displayed rep-
resents the amino acid similarity between the respective pro-
tein and human Ape1. Only mammals have acquired the re-
dox function.
the repair function (Fig. 3), whereas mutation of a variety of
amino acids required for DNA repair activity, such as His309
(H309) and others (51) (Fig. 3) does not affect the redox func-
tion]. Whereas the DNA-repair active site of Ape1 has been
clearly delineated (26), the redox domain or region is less ob-
vious. It appears that the only required Cys for full redox
function is Cys65, which is buried within the Ape1 protein
(Fig. 3). This was recently confirmed by Georgiadis and her
co-workers (25) when they mutated a Thr (T) in zebrafish
Ape1 located at the same position of the Cys in mammalian
Ape1s to a Cys, and the subsequent protein gained redox
function (25).
Interestingly, the zebrafish crystal structure is quite simi-
lar to human Ape1, but only five of the seven Cys found in
mammalian Ape1s are structurally conserved. The two that
are not conserved are Cys65 and Cys138 (25). An evolution-
ary analysis of the Cys residues within vertebrates suggests
that the presence of Cys65 distinguishes mammalian from
nonmammalian vertebrate sequences (25).
The importance of Ape1 to the cell is demonstrated by the
fact that it has not been possible to generate an animal knock-
out model. Ape1 mouse knockouts are embryonic lethal on
days E5 to E9, and no viable cell lines have been established
that are completely deficient for Ape1 (79). Previously, a
small number of studies using DNA antisense methods have
implicated Ape1 in cellular resistance to a variety of agents
(6, 16, 59, 74). By using antisense Ape1, hypersensitivity of
human HeLa, rat glioma, or human lung carcinoma cells to
alkylating and oxidative agents as well as ionizing radiation
but not UV radiation was indicated (16). More recently, a
similar enhanced sensitivity for osteogenic sarcoma cells to
DNA-damaging agents has been reported (75). Cells lacking
Ape1 activity are hypersensitive to alkylating agents that in-
duce the formation of AP sites (13, 24). Targeted reduction
of Ape1 protein by specific anti-sense oligonucleotides ren-
ders mammalian cells hypersensitive to methylmethane sul-
fonate (MMS), H2O2, bleomycin, temozolomide (TMZ), and
gemcitabine (2, 32, 43, 59, 74). Additionally, blocking the re-
pair function of Ape1 has led to enhanced effectiveness of
DNA-damaging agents such as temozolomide (TMZ), and
other alkylating and oxidative DNA-damaging agents
(19–21, 30, 44–47, 51, 70, 75, 81). Finally, blocking the activ-
ity of Ape1 after IR has lead to an increase in tumor cell
killing (37, 68, 73).
However, the use of antisense methods in cancer cells re-
moves not only the repair function of Ape1, but also its re-
dox function and all protein–protein interactions mediated
by Ape1. Ape1 is thought to interact with a large number of
other repair-related proteins including Ogg1 (66), DNA gly-
cosylases, DNA polymerase  (61), x-ray cross-complement-
ing-1 (XRCC1) (4, 53, 61), proliferating cell nuclear antigen
(PCNA) (14), Cockayne syndrome B (CSB) (78), and flap en-
donuclease 1 (FEN1) (14, 61, 64).
Additional functions that have been ascribed to Ape1 also
complicate its analysis with siRNA. For example, it has been
implicated in nucleotide incision repair (NIR) (76), involved
in NK cell–mediated killing through granzyme A (GzmA)
(17, 50), prevents oxidative stress by negatively regulating
Rac1/GTPase activity(60), regulates endothelial NO pro-
duction and vascular tone (38), and in a recent finding that
is important for our studies, Ape1 appears to suppress the
activation of PARP1 [poly (ADP-ribose) polymerase 1] dur-
ing the repair process of oxidative DNA damage, which may
allow cells to avoid cell death (63). Other findings of a rela-
tion between Ape1 and Bcl2 levels (39) and acting as a neg-
ative regulator of the parathyroid hormone gene have been
shown (1, 11, 42, 58). Finally, recent data link Ape1 with
PTEN (18), a major tumor suppressor that has been impli-
cated as playing a crucial role in a variety of cancers, in-
cluding brain tumors (5).
Thus, by using antisense RNA or similar technology, it
will not be possible to determine precisely the role of the en-
donuclease or redox function of Ape1 in cancer or normal
cells without specific inhibitors of each function indepen-
dently. Therefore, with the long-term goal of developing can-
cer therapeutic agents, as well as small-molecule inhibitors
of each the major functions of Ape1, we present data further
characterizing the Ape1 redox mechanism of action and
demonstrating the role of the redox function of Ape1 in can-
cer and retinal endothelial cells (RECs) in survival and
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FIG. 3. Cartoon of major amino acids
involved in the DNA repair or redox
function of Ape1. (A) Seven cysteines ex-
ist in Ape1, but only Cys65 appears to be
involved in redox activity. Of the Cys
residues, Cys65 is unique to mammals
(25). The lower left panel (B) shows the rel-
ative positions of the seven Cys residues
on a ribbon rendering of Ape1. The lower
right two panels demonstrate that Cys65 is
a buried residue. All atoms of Ape1 are
shown in a van der Waals surface render-
ing in (C), with C65 in green and P112 in
red. (D) A molecular surface rendering
colored in the same way and in the same
orientation as in (C). Cys 65 is not visible
because it is not surface accessible (i.e., it
is buried). (For interpretation of the refer-
ences to color in this figure legend, the
reader is referred to the web version of this
article at www.liebertonline.com/ars).
growth by using a specific small-molecule inhibitor of just
the redox function of Ape1. Inhibition of the redox function
blocks endothelial cell growth and blocks the growth of tu-
mor cell lines as a single agent. This effect is independent of
the Ape1 DNA-repair function.
Materials and Methods
Synthesis of E3330, 3-[5-(2,3-dimethoxy-6-methyl-1,4-
benzoquinoyl)]-2-nonyl-2-propionic acid
Reagents were used as received from commercial sources.
THF and CH2Cl2 were distilled before use, and acetone was
dried over activated 4-Å molecular sieves for 2 h under ar-
gon. Flash chromatographic separations were performed by
using 32- to 63-m silica gel; thin-layer chromatography was
performed with Analtech 250-m GHLF plates with 254-nm
fluorescent indicator. All 1H-NMR spectra were obtained on
a Bruker 300-MHz NMR equipped with a multinuclear (1H,
13C, 19F, and 31P) 5-mm probe. 1H spectra were calibrated to
CHCl3 at 7.24 ppm. 13C NMR was calibrated to CHCl3 at 77.0
ppm. Elemental analyses were performed at the Purdue Uni-
versity Microanalysis Laboratory by Dr. Daniel Lee.
1,2,3,4-Tetramethoxybenzene (2)
By following a modified procedure by Tremblay et al. (72),
2,3,4-trimethoxybenzaldehyde 1 (6.08 g, 31.0 mmol) was dis-
solved in MeOH (60 ml), and then H2SO4 (0.6 ml) and 35%
aq. H2O2 (4.0 ml, 40 mmol) was added at room tempera-
ture. The reaction was then heated at reflux for 2 h. The so-
lution was cooled and extracted with ethyl acetate. The lay-
ers were separated, and the organic layer was washed with
brine, dried over MgSO4, and filtered. Flash chromatogra-
phy (1:4 EtOAc:hexanes) gave 2,3,4-trimethoxyphenol (5.56
g, 98%) as a light-red oil. Rf  0.29 (1:4 EtOAc:hexanes); 1H
NMR (CDCl3):  3.79 (s, 3H); 3.87 (s, 3H); 3.94 (s, 3H); 5.34
(bs, 1H, OH); 6.57 (q, 2H).
The intermediate phenol (3.85 g, 20.9 mmol) was dissolved
in dry acetone (90.0 ml), and K2CO3 (9.36 g, 67.7 mmol) was
added, followed by MeI (9.0 ml, 140 mmol). The reaction
mixture was heated under reflux for 26 h, cooled to room
temperature, and filtered. The solvent was removed under
reduced pressure, and the residue was taken up in CH2Cl2
(50 ml). The suspension was filtered, dried over MgSO4, fil-
tered again, and condensed. The crude product was purified
by either flash chromatography (1:4 EtOAc:hexanes) or re-
crystallization from Et2O/hexanes to provide 2 (3.41 g, 82%)
as white needles, mp  86–87°C (Lit. 87–87.5°C) (3). 1H NMR
(CDCl3):  3.80 (s, 6H); 3.88 (s, 6 H); 6.56 (s, 2H).
6-Methyl-2,3,4,5-tetramethoxybenzaldehyde (3)
By following a modified procedure by Hansen et al. (28),
tetramethoxybenzene 2 (2.40 g, 12.1 mmol) was added to a
100-ml flame-dried round-bottom flask to which THF (50 ml)
was added. The solution was cooled to 0°C, and n-BuLi (2.5
M in hexanes, 6.0 ml, 15 mmol) was added slowly at 0°C.
The solution was stirred for 1 h at 0°C; then MeI (1.2 ml, 19.3
mmol) was added slowly, the reaction was stirred at 0°C for
2 h, and the reaction mixture was warmed to room temper-
ature and stirred an additional hour. The reaction was acid-
ified with dilute HCl, washed twice with brine, dried over
MgSO4, filtered, and condensed. After flash chromatography
(1:9 EtOAc/hexanes), the tetramethoxytoluene product was
collected as a yellow oil (2.27 g, 88%). Rf  0.57 (7:13
EtOAc:hexanes); 1H NMR (CDCl3):  2.43 (s, 3H); 3.74 (s, 3H);
3.89 (s, 3H); 3.92 (s, 3H); 4.00 (s, 3H); 10.41 (s, 1H).
According to the procedure by Ohkawa et al. (57), tetram-
ethoxytoluene (0.690 g, 3.25 mmol) was dissolved in CH2Cl2
(2.0 ml) in a flame-dried 25-ml round-bottom flask and
cooled to 0°C. ,-Dichloromethyl methyl ether (0.85 ml, 9.6
mmol) was then added at 0°C, followed by TiCl4 (1 M in
CH2Cl2, 9.0 ml, 9.0 mmol) at 0°C. The reaction was warmed
slowly to room temperature and stirred for 6 h under argon.
The reaction was then poured into chilled water and stirred
for 10 min. The reaction was diluted with EtOAc, washed
with brine, dried over MgSO4, filtered, and condensed. The
crude oil was then purified by flash chromatography (3:17
EtOAc:hexanes) to provide 3 (0.696 g, 89%) as a yellow oil.
Rf  0.26 (3:17 EtOAc:hexanes); 1H NMR (CDCl3):  2.44 (s,
3H); 3.74 (s, 3H); 3.89 (s, 3H); 3.92 (s, 3H); 4.00 (s, 3H); 10.24
(s, 1H).
Ethyl (E)-3-(6-methyl-2,3,4,5-tetramethoxyphenyl)-2-
nonylpropenoate (4)
By following modification to the procedure by Shinkawa
et al. (55), NaH (0.24 g, 10.0 mmol) was added to a flame-
dried 50-ml three-neck round-bottom flask connected to a
water-jacketed reflux condenser. The flask was purged with
argon, and a drying tube was attached to the top. THF (15
ml) was added to the flask, followed by triethyl 2-phospho-
noundecanoate (1.90 g, 5.44 mmol) dissolved in THF (5 ml)
at room temperature. The reaction was heated under reflux
for 30 min, and then aldehyde 3 (1.04 g, 4.32 mmol) was dis-
solved in THF (8 ml) and added slowly under reflux. The re-
action was stirred for another 3 h under reflux and was then
cooled, acidified with dilute HCl, diluted with ethyl acetate,
and washed with brine. The organic layer was dried
(MgSO4), filtered, and condensed. The resulting oil was pu-
rified via flash-column chromatography (3:17 EtOAc:hexa-
nes) to provide 4 (1.28 g, 68%) as a colorless oil. Rf  0.40
(3:17 EtOAc:hexanes); 1H NMR (CDCl3):  0.84 (t, 3H); 1.08
– 1.22 (m, 11H); 1.24 – 1.35 (m, 3H); 1.33 (t, 3H); 2.03 (s, 3H);
2.12 (m, 2H); 3.69 (s, 3H); 3.78 (s, 3H); 3.88 (s, 3H); 3.93 (s,
3H); 4.25 (q, 2H); 7.37 (s, 1H).
(E)-3-(4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-
dienyl)-2-nonylpropenoic acid (5)
Ester 4 (1.57 g, 3.60 mmol) was dissolved in EtOH (12 ml),
and then KOH (0.41 g, 7.3 mmol) was added. The solution
was heated to reflux and stirred for 30 min. The reaction was
then cooled, acidified with HCl, and extracted with ethyl ac-
etate. The organic layer was washed with brine, dried over
MgSO4, filtered, and condensed. The resulting acid was then
used in the following reaction without purification. Alter-
natively, the product can be purified via flash chromatogra-
phy (2:3 Et2O:hexanes 0.5% AcOH) to provide the free acid
(1.43 g, 97%) as a colorless oil: Rf  0.36 (2:3 Et2O:hexanes
0.5% AcOH).1H NMR (CDCl3):  0.84 (t, 3H, J  6.9 Hz); 1.13
(m, 12H); 1.36 (m, 2H); 2.04 (s, 3H); 2.14 (m, 2H); 3.70 (s, 3H);
3.79 (s, 3H); 3.89 (s, 3H); 3.93 (s, 3H); 7.54 (s, 1H).
By following modifications to the procedures by Shinkawa
et al. and Flader et al. (23, 56), the crude acid obtained ear-
lier (1.13 g, 2.77 mmol) was dissolved in ethyl acetate (15.0
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ml) at room temperature; then HNO3 (1.5 ml) and AcOH (6
drops) were added, and the reaction was stirred for 4 h. The
mixture was then diluted with EtOAc (20 ml) washed with
brine, dried over MgSO4, filtered, and condensed. The red
oil was then purified by either flash column chromatogra-
phy (2:3 Et2O/hexanes, 0.5% AcOH) or recrystallization from
Et2O/hexanes to afford 5 (0.443 g, 42%) as a red solid; mp 
56–57°C (Lit. 68°C) (56). Elemental analysis: calc C, 66.65%,
H, 7.99%; found C, 66.32%, H, 7.89%. 1H NMR (CDCl3): 
0.84 (t, 3H), 1.18 (bs, 14H); 1.39 (bs, 2H); 1.94 (d, 3H); 2.09 (t,
3H); 3.99 (s, 3H); 4.02 (s, 3H); 7.26 (d, 1H).
Expression and purification of proteins
Proteins were purified as previously described (25, 29, 36,
40, 80).
Ape1 DNA repair assays
Oligonucleotide gel-based Ape1 endonuclease activity as-
says were performed as previously described (20, 41). The
base excision repair (BER) pathway analysis was performed
as described (67).
Redox assays
Electrophoretic mobility shift assay (EMSA). EMSAs were
performed as described (15) with the following modifica-
tions. The 10-g/l purified Ape1 protein was reduced with
1.0 mM DTT at 370C for 10 min and diluted in PBS buffer to
yield final concentrations of 2 g/l protein and 0.2 mM
DTT. Two l of reduced Ape1 protein was added to EMSA
reaction buffer [10 mM Tris (pH 7.5), 50 mM NaCl, 1 mM
MgCl2, 1 mM EDTA, 5% (vol/vol) glycerol] with 6 g of nu-
clear extract (treated with 0.01mM diamide for 10 min) from
Hey-C2 cells as the source of AP1 protein in a total volume
of 18 l and incubated for 30 min. at room temperature. 
One l poly(dI-dC)  poly(dI-dC) (1g/ul) (Amersham Bio-
sciences, Piscataway, NJ) was added for 5 min followed by
1 l of the 5 hexachloro-fluorescein phosphoramidite
(HEX)-labeled double-stranded oligonucleotide DNA (The
Midland Certified Reagent Company, Midland, TX) con-
taining the AP-1 consensus sequence (5CGCTTGAT-
GACTCAGCCGGAA-3) (0.1 pmol), and the mixture was
further incubated for 30 min at room temperature. The final
concentration of DTT in the redox reactions was 0.02 mM.
Samples were loaded on a 5% nondenaturing polyacry-
lamide gel and subjected to electrophoresis in 0.5X TBE
buffer (200 V for 1 h at 4°C) and detected by using the Hi-
tachi FMBio II Fluorescence Imaging System (Hitachi Genetic
Systems, South San Francisco, CA). The HEX fluorophore is
excited by a solid-state laser at 532 nm (Perkin-Elmer) and
emits a fluorescent light signal at 560 nm, which is then mea-
sured using a 585-nm filter.
Transactivation assay
E3330 assays. SKOV-3X and Hey-C2 ovarian cancer cell
lines were co-transfected with the NF-B-Luc or AP-1-Luc
genes (luciferase gene with the NF-B or AP-1 responsive
promoter) by using plasmid pNF-B-Luc or pAP-1-Luc
(Stratagene, La Jolla, CA) and lipofectamine TM 2000 (Invit-
rogen Life Technologies, Carlsbad, CA). The cells were co-
transfected with a control pcDNA empty vector plasmid,
pcDNA-wtApe1 or the redox mutant, pcDNA-C65A, and a
Renilla luciferase control reporter vector pRL-CMV (Promega
Corp., Madison, WI) in a 10:1 ratio by using lipofectamine
TM 2000. After 24-h transfection, cells were lysed, and the
Firefly and Renilla luciferase activities were assayed by using
the Dual Luciferase Reporter Assay System (Promega Corp.)
with Renilla luciferase activity for normalization in a 96-well
microtiter plate luminometer (Thermolabs Systems,
Franklin, MA). All of the transfection experiments were per-
formed in triplicate and repeated at least 3 times in inde-
pendent experiments.
Ape1 transactivation mutation assays. The stable Skov-3X
ovarian cancer cell line with NF-B-Luc gene (luciferase gene
with the NF-B–responsive promoter) was established by
transfecting Skov-3X cells with plasmid pNF-B-Luc (Strat-
agene) by using lipofectamine TM 2000 (Invitrogen Life
Technologies) and screening the luciferase-positive colonies
by using a Luciferase Assay Kit (Promega Corp.). The stable
Skov-3X cells with the NF-B-Luc gene were cotransfected
with plasmid pcDNA-wtApe1 or the redox mutant pcDNA-
C65A and a Renilla luciferase control reporter vector pRL-
CMV (Promega Corp.) in a 1:10 ratio by using lipofectamine
TM 2000. The analysis was conducted as described earlier
for the E3330 studies.
Cell survival/killing assays
3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymeyhoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium (MTT) dye assay for cell
growth was performed as previously published (20, 75).
Murine retinal endothelial cell isolation and culture
Mouse retinal vascular endothelial cells (RVECs) were iso-
lated as described before with modifications (69). In brief,
retinal tissues from young adult wild-type mice carrying a
SV40 transgene from the Charles River Laboratories (Im-
mortoMouse) were digested with 0.2 mg/ml collagenase
type I (Worthington, Lakewood, NJ) in DMEM at 37°C for 3
h. After titration and filtration through a 40-m nylon mem-
brane (Fisher Scientific, Hanover Park, IL), the dissociated
cells were incubated with sheep anti-rat magnetic beads (Dy-
nal Biotech, Lake Success, NY) precoated with a rat anti-
mouse PECAM-1 monoclonal antibody (BD Biosciences, San
Jose, CA) for affinity binding at 4°C for 45 min. Bead-bound
cells were separated by magnetic force, plated in a 24-well
plate precoated with 2 g/ml of human fibronectin (BD Bio-
sciences, San Jose, CA) and grown in an endothelial growth
media (EBM-2MV, Cambrex). Cells were allowed to grow
out of the beads reaching confluence for 10 days before us-
ing for assays.
Cell-proliferation assay
Equal numbers of RVECs were seeded at 2,000 cell/well
in a 96-well plate. Cells were cultured with or without 10
ng/ml recombinant mouse basic fibroblast growth factor
(bFGF; R&D Systems, Inc.) supplement in various concen-
trations of E3330 (10, 25, 50, 100 M). Each group consisted
at least five wells (n  5) including a vehicle control group.
Two days after seeding, the total number of cells was as-
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sayed by using the CellTiter 96 AQueous One Solution
(Promega Corporation). The proliferation rate was calculated
according to manufacturer’s instructions. Proliferations of
RVECs from different groups were compared with the ve-
hicle control group for statistical significance.
Tube-formation assay
Matrigel (BD Biosciences, Bedford, MA) was used to coat
each well (50 l) of a precooled 96-well plate. RVECs at 5,000
cells per well were seeded and incubated in EBM with 1%
FBS and 10-ng/ml bFGF at 37°C for 24 h. The formation of
capillary-like structures by RVECs on the Matrigel was quan-
tified by counting the number of closed tube units in each
well. The percentage of the tube formation to the vehicle con-
trol group was calculated for each E3330 (1, 5, 20 M) treated
group (n  3).
Results
A number of studies have implicated Cys65 in the redox
function of Ape1. However, some disagreement still exists
whether this Cys is the only Cys involved, or just the major
Cys involved in redox activity. Recent data using a zebrafish
Ape1 (zApe1) model demonstrates that the acquisition of the
Cys65 in human Ape1 converts a redox-inactive zApe1 to a
redox-active zApe1 (25). To confirm this, we mutated the
Cys65 in human Ape1 to an Ala (A) and performed cellular
transactivation reporter analysis by using AP-1 and NF-B
as the downstream targets of Ape1 (Fig. 4). When Cys65 is
mutated to Ala, Ape1 loses all of its redox activity in this
cell-based reporter system, whereas addition of wild-type
Ape1 results in enhanced redox activity (Fig. 4), regardless
of the downstream target.
Our next series of experiments involved the use of a small
molecule redox inhibitor of Ape1, 3-[5-(2,3-dimethoxy-6-
methyl-1,4-benzoquinoyl)]-2-nonyl-2-propionic acid (E3330)
(82). This molecule has previously been shown to block Ape1
function in studies with NF-B (35) and in hematopoietic
cells (82) and is very specific for Ape1 with a high binding
affinity and specificity (34, 65). To continue these studies,
E3330, which is not commercially available, had to be syn-
thesized by using a new approach, which we developed and
described in the Methods section. This route was developed
after encountering difficulties with the previously reported
synthetic route (22, 23, 55). The result of this synthesis is
shown in Fig. 5.
By using E3330 in a series of EMSA experiments, we dem-
onstrate that E3330 blocks the redox function of Ape1 with
AP-1 as the downstream target in vitro (Fig. 6A) as well as
after the treatment of ovarian cancer cells with E3330 (Fig.
6B). Additionally, we demonstrate that E3330 blocks Ape1
redox activity with HIF-1 demonstrating that the redox in-
hibition is not specific for the downstream target (Fig. 6C).
Similar results with NF-B in EMSA studies have also been
observed (data not shown).
Although E3330 blocked the redox function of Ape1, it had
no effect on Ape1 repair endonuclease activity (Fig. 7A), nor
did it affect the ability of proteins involved in the BER path-
way to perform the repair of AP sites (Fig. 7B) by using the
established BER-pathway assay (67). These studies demon-
strate the specificity of E3330 for the redox, but not the re-
pair function of Ape1.
As an additional approach to demonstrate the specificity
of E3330 to Ape1, we used the mutant zebrafish (T58C),
which had been converted from a redox-inactive Ape1 pro-
tein to a redox-active protein (25), and reacted it with E3330.
We then performed the redox EMSA by using AP-1 as the
target protein. As shown in Fig. 8, E3330 blocked the ability
of the T58C zebrafish Ape1, which had acquired the redox
function, in a similar fashion to that with which it blocks hu-
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FIG. 4. Effect of human Ape1 and Cys65 redox
Ape1 mutant on NF-B and AP-1 transactivation
in a cell-based reporter assay system. SKOV-3X
cells were transfected with AP-1 or NF-B–Luc con-
struct containing an NF-B or AP-1–response pro-
moter and driving the expression of a luciferase
gene. The cells were cotransfected with plasmid
pcDNA–wild-type hApe1 or the redox mutant
(pcDNA-C65A) and a Renilla luciferase control re-
porter vector pRL-CMV. After a 24-h transfection
period, cells were lysed, and Firefly and Renilla lu-
ciferase activities were assayed by using Renilla lu-
ciferase activity for normalization. All of the trans-
fection experiments were performed in triplicate
and repeated at least 3 times in independent ex-
periments. Data are expressed as mean  standard
error from a representative experiment, and Stu-
dent’s t tests were performed. *Significant differ-
ence at the p  0.05 level comparing the Cys65 mu-
tant and wt-Ape1 and wt-Ape1 and mock or
pcDNA.
man Ape1 redox activity. The concentration of E3330 re-
quired to inhibit 50% of the redox activity was 6.5 M for
wild-type hApe1 and 5 M for T58C zApe. Although not
conclusive, these data demonstrate that E3330 is not affect-
ing the other cysteines in the Ape1 proteins and that the
Cys65 in human Ape1 is the primary target of E3330 and the
main cysteine involved in the redox function of Ape1. This
was further confirmed in studies in which we mutated each
cysteine in human Ape1 individually, and only the Cys65
had any major effect on the redox function of Ape1 (data not
shown). Experiments are in progress to demonstrate un-
equivocally the interaction of E3330 and Ape1 protein and
the mechanism involved (Georgiadis and Kelley, personal
communication, 2008).
Further to confirm the activity of E3330 as an Ape1 redox
inhibitor in cell-based assays, we co-transfected two ovarian
cancer cell lines, Hey-C2 and SKOV-3X, with either the pNF-
B-Luc or pAP-1-Luc constructs and the Renilla luciferase re-
porter vector pRL-CMV as a control for transfection. After
transfection, we treated the cells with increasing amounts of
E3330. As observed in Fig. 9, increasing amounts of E3330
causes an analogous decrease in the amount of AP-1 or 
NF-B activation, as evidenced by a decrease in the amount
of AP-1 or NF-B activation of the luciferase reporter gene.
These results indicate decreased binding of these proteins
due to the blockage of their conversion from an oxidized to
a reduced state by Ape1 because of E3330 blocking Ape1 re-
dox function.
Because E3330 does not affect the repair functions of Ape1,
as shown in Fig. 7, we tested the effect of blocking Ape1 re-
dox function on two ovarian cancer cell lines. As shown in
Fig. 10, E3330 causes a decrease in the amount of cell pro-
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FIG. 5. Synthesis of 3-[5-(2,3-dimethoxy-6-
methyl-1,4-benzoquinoyl)]-2-nonyl-2-propi-
onic acid (E3330) by using a novel approach.
FIG. 6. EMSA studies of AP-1
or HIF-1 binding after E3330
treatments. Increasing levels of
E3330 decrease purified c-Jun
binding in vitro (A) and in SKOV-
3X ovarian cancer cells treated
with E3330 (B). HIF-1 is also a
downstream target of the redox
function of Ape1, and inhibition
of Ape1 redox by E3330 blocks
HIF-1 binding (C). (D) A West-
ern blot analysis of the samples
in (B) by using Ape1 and AP-1
antibodies, demonstrating that
the level of Ape1 and AP-1 in the
cell extracts was identical, and
the results observed are not due
to a decrease in the respective
proteins.
liferation with increasing amounts of drug on both cell lines
with an IC50 of 33 and 37 M, respectively. We observed
similar results with other cancer cell lines (data not shown).
These results indicate that the redox activity functions of
Ape1 in the growth or survival response of the cancer cells
is independent of the DNA repair activity of Ape1. These
findings confirm similar findings we observed in a hemato-
poietic model of embryonic stem cells (82). Further mecha-
nistic studies as to how this is occurring are currently under
way, although preliminary studies indicate that the redox-
inhibitory effect is not necessarily due to cell killing, but to
a block in cell proliferation or cytostatic effect similar to that
observed by using Ape1 siRNA in vivo (19, 20).
E3330 inhibits RVEC proliferation and 
angiogenesis in vitro
Proliferation of endothelial cells (ECs) is an important in-
dex for the angiogenic ability of EC in vitro. The MTS assay
is a simple and highly reproducible method of quantifying
cell proliferation and was used to determine the effect of
E3330 on the proliferation rate of RVECs. As shown in Fig.
11A, addition of E3330 inhibited RVEC growth in a dose-de-
pendent manner. Supplement of bFGF in the basal media
significantly boosted the proliferation rate. However, a sim-
ilar inhibition effect was still evident with various doses of
E3330 treatments. The difference between each E3330-treated
group and its corresponding vehicle control of the same
medium was statistically significant (p  0.01).
An in vitro angiogenesis assay also was used to determine
the effect of E3330 on RVEC formation of capillary-like struc-
tures on Matrigel. The inhibition effect of E3330 was similar
to the proliferation assay but in a much lower dose range
(Fig. 11B). E3330 at 1 M was sufficient to elicit a 30% re-
duction of tube formation. Quantitative measurement of the
number of tube units revealed that the difference was sta-
tistically significant (p  0.05). The tube formation was com-
pletely abolished at 5 M or higher concentration.
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FIG. 7. Oligonucleotide gel-based endonuclease and BER assays. Analysis was performed as described in Methods (20,
41). (A) One nanogram of purified Ape1 protein was used with an increasing amount of E3330, as indicated above the gel
lanes. Ape1 protein extracts were added to a reaction mixture containing 0.2 pmol of HEX-labeled double-stranded tetrahy-
drofuran oligonucleotide, 50 mM HEPES, 50 mM KCl, 10 mM MgCl2, 2 mM DTT, 1% BSA, and 0.05% Triton X-100 (pH
7.5). Reactions with or without E3330 were incubated for 15 min at 37°C. Reactions were halted by adding 10 l of for-
mamide. Ape1 assay products were separated on a 20% polyacrylamide gel containing 7 M urea. The upper band (26-mer)
represents uncleaved AP oligonucleotides, whereas the lower band (14-mer) is the reacted oligonucleotide. (B) BER path-
way in vitro analysis by using the gap-filling assay, as described by Singhal et al. (67). The gap-filling assay is initiated from
a uracil in an oligonucleotide substrate, which is then removed by using uracil-glycosylase. If the BER pathway is fully func-
tional, a 48-mer band will be observed on the gel, whereas a 21-mer band indicates incomplete BER-pathway activity. E3330
was added to the reactions, as indicated, and had no effect on the pathway, indicating no effect on Ape1-repair function.
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These results demonstrate that inhibition of redox activ-
ity significantly attenuates RVEC proliferation and capillary
formation in vitro. The capillary formation of RVECs appears
much more sensitive to redox inhibition.
Discussion
It has long been recognized that DNA-damaging agents
are useful in killing cancer cells and are still the mainstay of
cancer treatments (31, 49). However, a significant problem
with the success of DNA-damaging agents is the upregula-
tion or activation of a number of different pathways that con-
fer resistance of the cancer cells to the treatment with DNA-
damaging agents. This includes pathways such at those
involved in signaling, multidrug resistance, cell-cycle check-
points, antiangiogenesis, and others as potential approaches
to treat and kill cancer. Much less work has focused on block-
ing the ability of a cancer cell to recognize and repair the
damaged DNA that results from front-line cancer treatments
(chemotherapy and radiation). One of these systems includes
DNA-repair enzymes, such as Ape1, leading to resistance
and failure of the agent to kill the cancer cells (16, 21). These
findings suggest that one possible strategy for preventing re-
sistance and improving efficacy of the DNA-targeting agents
would be to inhibit the DNA-repair enzyme responsible for
resistance. This potential has been recognized, as evidenced
by the identification of small-molecule inhibitors of several
DNA-repair enzymes, including MGMT, polyADP-ribose
polymerase (PARP1), ataxia–telangiectasia mutated kinase
(ATM kinase), Ape1, and DNA PKcs in varying degrees of
success and development (12, 21, 48).
Toward the goal of developing inhibitors of Ape1 as a po-
tential cancer therapeutic, as well as developing specific, in-
dependent inhibitors of each of the major functions of Ape1
(redox and repair), we focused on the blocking of the Ape1
redox function. Although overwhelming evidence supports
the observation that Cys65 is the main cysteine involved in
the redox role of human Ape1, we further confirm this
premise through site-directed mutagenesis of the Cys65 site,
leading to the lack of NF-B or AP-1 transactivation in a cell-
model system (Fig. 4) and inhibition of Ape1 redox by us-
ing a small molecule–specific inhibitor, E3330 (Figs. 6 and 9).
Furthermore, we demonstrate that the humanized zebrafish
Ape1, which we previously demonstrated gained redox ac-
tivity (25), is now inhibited by E3330 (Fig. 8). In addition, the
redox inhibition of Ape1 has no effect on the repair function
of Ape1, demonstrated by the lack of inhibition in two sep-
arate DNA-repair assays (Fig. 7). E3330 was also able to block
the redox function of Ape1 in two ovarian cancer cell lines
by using a transactivation reporter assay in a dose-depen-
dent manner (Fig. 9). These data support the cellular role of
Ape1 in redox activation of downstream targets and dem-
onstrate E3330 as a small molecule to block transcription-fac-
tor activation; particularly transcription factors that are in-
volved in cancer cell growth and proliferation, such as
NF-B, AP-1, and HIF-1. These data are in line with our
previous findings demonstrating that blocking the redox, but
not repair function of Ape1 led to blocking cell proliferation
(82). Although previous studies demonstrated that altering
Ape1 levels leads to blockage of cell growth and increased
cancer cell sensitivity (2, 6, 16, 19, 20, 30, 33, 37, 43–47, 51,
59, 68, 70, 73–75, 81), these studies used overexpression of
Ape1, Ape1 antisense oligonucleotides, or Ape1 siRNA: The
quandary with this approach, although valid, is that each of
these approaches changes the total cellular content level of
Ape1 and removes all of the Ape1 functions, not just the re-
pair or redox activities. Because Ape has multiple functions
as well as protein–protein interactions with other DNA re-
pair and signaling proteins, the increase or decrease of Ape1
protein may result in prejudiced or inexact results. Use of
specific small-molecule inhibitors such as E3330 will be im-
portant to delineate the true role of Ape1 in various cancer,
disease, and normal cellular functions. Ultimately, using
Ape1 redox inhibitors with Ape1-specific endonuclease re-
pair inhibitors will give a clearer picture of the multiple ac-
tivites of Ape1.
Toward the goal of developing specific Ape1 redox inhibi-
tion to study this role of Ape1 in normal and cancer cells, we
performed single-agent dose–response studies by using E3330
in ovarian cancer cell lines and determined that E3330 does
have single-agent cancer cell killing abilities (Fig. 10). This find-
ing is not restricted to just ovarian cancer cell lines and has been
observed with cell lines representing colon, lung, breast, brain,
pancreatic, prostate, and multiple myeloma cancers (data not
shown). In contrast, we do not see significant growth inhibi-
tion in our studies with normal cells, such as hematopoietic em-
bryonic cells (82), or in RVEC (Fig. 11) E3330 inhibits RVEC cell
growth (MTS assay in the results). Additionally, we do not see
cell killing in human CD34 progenitor cells (unpublished
FIG. 8. Redox EMSA showing E3330 inhibition of mutant
zebrafish Ape1. An increasing amount of E3330 was incu-
bated with 2 l purified hApe1(lanes 1–7) or mutant ze-
brafish Ape1 (T58C-zApe1) (lanes 8–13; reduced with 1.0
mM DTT and then diluted to 2 g/l with 0.2 mM DTT in
PBS) in EMSA reaction buffer [10 mM Tris (pH 7.5), 50 mM
NaCl, 1 mM MgCl2, 1 mM EDTA, 5% (vol/vol) glycerol]
with a total volume of 10 l for 30 min, and then the EMSA
assay was performed. E3330 inhibited the AP1-DNA bind-
ing stimulated by hApe1 and T58C-zApe1 to the same ex-
tent. Lane 1 is unreduced hApe1 control; lane 2 is control for
DTT carryover, and lane 13 is unreduced T58C-zApe1 con-
trol. Lanes 3–7 are the human Ape1 reacted with increasing
amounts of E3330. Lanes 8–12 show T58C zebrafish Ape1 re-
acted with increasing amounts of E3330.
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data). These data are novel in that they implicate the redox role
of Ape in cancer, but not in “normal” cell survival. This impli-
cates the redox role as independent of the Ape1 DNA-repair
function and independent of the addition of DNA-damaging
agents. This is supported by our recently published data in
ovarian cancer studies in xenografts, demonstrating that the
knockdown of Ape1 results in the blocking of cell growth and
proliferation, but not cell death (19). This is the first time can-
cer cell killing has been reported by using a small-molecule in-
hibitor of Ape1 redox function.
One of the most exciting results presented here details the
potential role of Ape1 in angiogenesis (Fig. 11). As demon-
strated in our RVEC studies, inhibition of Ape1 redox func-
tion by using E3330 blocks RVEC cell growth, even with
bFGF stimulation (Fig. 11). Additional studies using RVEC
formation of capillary-like structures on Matrigel resulted in
the decreased angiogenesis, as measured by this assay, but
at a much lower dose range than in the MTS assays (Fig. 11).
These results demonstrate that inhibition of redox activity
significantly attenuates RVEC proliferation and capillary for-
mation in vitro, but does not cause cell death. Furthermore,
the capillary formation of RVECs appears much more sen-
sitive to redox inhibition of Ape1 than the proliferation. This
is the first time this role of Ape1 has been clearly demon-
strated, and it necessitated the use of a specific small-mole-
cule Ape1 redox inhibitor to identify this novel activity.
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FIG. 10. Cell-growth assay by using E3330 on two ovarian cancer cell lines. The MTT growth/survival assay was per-
formed as described in Methods. Increasing amounts of E3330 resulted in decreasing cell growth and decreased cell num-
bers. Data are expressed as the mean  SEM of three independent experiments performed in triplicate.
FIG. 11. Inhibition of redox activity of Ape1 reduces retinal vascular endothelial cell angiogenesis in vitro. (A) In the
MTS proliferation assay, RVECs were treated with or without bFGF and with various doses of E3330 (10–100 M) in the
culture for 2 days. A dose-dependent inhibition of RVEC growth was evident in both basal media (EBM) and bFGF-sup-
plemented (10 ng/ml) media (EBM  bFGF). The number of viable cells in all E3330-treated groups was significantly dif-
ferent (p  0.01) from its corresponding vehicle control cells in the same medium. (B) In the tube-formation assay, RVECs
cultured in bFGF medium on Matrigel were treated with various doses of E3330 (1–20 M) for 1 day. RVEC formation of
capillary-like structure was significantly inhibited at a much lower dose range. The 30% reduction of tube units in 1 M
E3330 was statistically different from the vehicle control (p  0.05).
As discussed, Ape1 was originally identified as the pri-
mary target of E3330. E3330 was immobilized on beads, and
Ape1 was identified from a nuclear extract of Jurkat cells
as a protein that specifically binds to E3330. By using sur-
face plasmon resonance, a kinetic constant (KD) of 1.6 nM
was obtained for the binding of E3330 to Ape1, suggesting
a specific interaction. It was further shown that E3330
blocked the ability of Ape1 to reduce NF-B, thus interfer-
ing with the redox activity of Ape1 (27, 35, 52, 65). Through
a series of N- and C-terminal truncation mutants, a peptide
including residues 72-88 of Ape1 was proposed to bind to
E3330, suggesting that E3330 interacts with a specific site
on Ape1 (34, 54, 65). However, we believe that this ap-
proach was imperfect, in that the truncated Ape1 molecules
are unlikely to fold correctly, and thus the identification of
the binding site is suspect. In addition, the proposed bind-
ing site is somewhat puzzling in light of the structure of
Ape1, as an obvious binding site is not noted (data not
shown). These residues (aa 72–80) form a ridge on the sur-
face of the molecule with no obvious cavities or binding
pockets that are sufficiently large to bind E3330. Currently,
we are pursuing studies to delineate the binding site or re-
gion of E3330 on Ape1.
In conclusion, Ape1 is a multifunctional protein with both
important DNA-repair and redox capabilities. However, to
delineate the various functions of Ape1, small-molecule in-
hibitors of each function will be necessary ultimately to con-
clude which function is required in normal and cancer cell
function. Additionally, we show data that demonstrate a
new role of Ape1 with its involvement in angiogenesis, and
subsequent inhibition of Ape1s redox function abrogates this
role. The use of E3330 and new analogues currently under
development will be critical reagents in the future studies of
the cellular functions of Ape1 and have potential therapeu-
tic applications.
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